NEUREN PHARMACEUTICALS LIMITED

1.03%

$13.71

Market Cap $1.716B

Healthcare Biotechnology

Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company developing... Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company developing therapies for neurodevelopmental disorders. The Company is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options. The Company’s product DAYBUE (trofinetide) is used to treat Rett syndrome in adults and pediatric patients two years of age and older. The United States (US) Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have both granted orphan drug designation to the Company for trofinetide in Fragile X syndrome. Its second product NNZ-2591 is in phase II clinical trials in Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome. The Company has granted an exclusive worldwide license to Acadia Pharmaceuticals Inc. for the development and commercialization of NNZ-259 for Rett syndrome and Fragile X syndrome.More

ASX:PAR

This stock could have something close to a cure for osteoarthritis. Paradigm Biopharmaceuticals (ASX:PAR) is a late-stage drug development company working first and foremost to create a superior treatment for osteoarthritis.

Latest Threads

Tag

Subject

NEU

Neuren Media and Analyst Coverage

27 28 29

03/06/25

1.6K

964K

03/06/25

Last post baldwidx

1.6K

964K

NEU

M&A

2 3 4

03/06/25

199

103K

03/06/25

Last post Anydaynow

199

103K

NEU

Share Price

257 258 259

03/06/25

15K

7.5M

03/06/25

Last post htae39

15K

7.5M

NEU

Ann: Update - Notification of buy-back - NEU

03/06/25

3.7K

03/06/25

Last post htae39

3.7K

NEU

Ann: Update - Notification of buy-back - NEU

02/06/25

1.2K

02/06/25

Last post What A Gas

1.2K

NEU

Katelin’s Turn is HERE!!!

4 5 6

02/06/25

319

201K

02/06/25

Last post Kryptonite

319

201K

NEU

NEU chart

37 38 39

30/05/25

2.3K

1.3M

30/05/25

Last post GmundStables

2.3K

1.3M

NEU

Ann: Update - Notification of buy-back - NEU

30/05/25

785

30/05/25

Last post Gjpe

785

See All Discussions

Timeline

Update - Notification of buy-back - NEU
03 Jun 08:38	Share

Update - Notification of buy-back - NEU
02 Jun 08:51	Share

Update - Notification of buy-back - NEU
30 May 08:41	Share

Update - Notification of buy-back - NEU
29 May 08:00	Share

Update - Notification of buy-back - NEU
28 May 07:31	Share

Results of Meeting
27 May 12:17	Share

AGM Chair Address & CEO Presentation
27 May 10:19	Share

Update - Notification of buy-back - NEU
27 May 08:41	Share

Update - Notification of buy-back - NEU
26 May 09:11	Share

Notification regarding unquoted securities - NEU
23 May 17:15	Share

Approval of long-term equity incentive
23 May 11:51	Share

Update - Notification of buy-back - NEU
23 May 08:43	Share

Update - Notification of buy-back - NEU
22 May 08:21	Share

Update - Notification of buy-back - NEU
21 May 07:31	Share

Update - Notification of buy-back - NEU
20 May 08:26	Share

Update - Notification of buy-back - NEU
19 May 08:52	Share

Update - Notification of buy-back - NEU
16 May 09:11	Share

Update - Notification of buy-back - NEU
15 May 08:00	Share

Update - Notification of buy-back - NEU
14 May 08:20	Share

NEU receives FDA minutes and re-confirms Phase 3 endpoints
13 May 14:06	Share

Update - Notification of buy-back - NEU
13 May 09:04	Share

Update - Notification of buy-back - NEU
12 May 09:09	Share

Update - Notification of buy-back - NEU
09 May 07:30	Share

Update - Notification of buy-back - NEU
08 May 09:08	Share

DAYBUE Q1 2025 net sales US$84.6m up 11% from Q1 2024
08 May 09:02	Share

Update - Notification of buy-back - NEU
07 May 07:31	Share

Notification of cessation of securities - NEU
06 May 08:51	Share

Update - Notification of buy-back - NEU
06 May 08:50	Share

Becoming a substantial holder
05 May 18:31	Share

Update - Notification of buy-back - NEU
05 May 09:14	Share

View More

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $13.71		Change 0.140(1.03%)		Mkt cap ! $1.716B

Open	High	Low	Value	Volume
$13.70	$13.91	$13.57	$4.235M	308.1K

Buyers (Bids)

No.	Vol.	Price($)
1	3664	$13.70

Sellers (Offers)

Price($)	Vol.	No.
$13.83	4115	1

View Market Depth

No.	Vol.	Price($)
1	3664	13.700
2	966	13.690
2	2902	13.680
5	5714	13.650
1	1302	13.610

Price($)	Vol.	No.
13.830	4115	1
13.860	7441	7
13.890	1302	1
13.900	120	1
13.930	1302	1

Last trade - 16.10pm 03/06/2025 (20 minute delay)


Last $13.75		Change 0.140 ( 0.85 %)
Open	High	Low	Volume
$13.75	$13.91	$13.59	72939
Last updated 15.59pm 03/06/2025 ?

NEU (ASX) Chart

NEUREN PHARMACEUTICALS LIMITED

Latest Threads

Site Activation and First Patient Consent in Australia for Phase 3 Knee OA Study

Timeline

Featured News

Latest Videos

Neuren Pharmaceuticals (ASX:NEU) partner drug approved as first treatment for Rett syndrome

13 Mar 2023 10:53 (AEDT)

Neuren Pharmaceuticals (ASX:NEU) receives FDA approval for Prader-Willi syndrome phase II trial

23 Jan 2023 11:16 (AEDT)

Latest Articles

FDA OK for Neuren's first ever Phase 3 trial in children with Phelan-McDermid syndrome

Neuren has popped 20% as the FDA greenlights its upcoming Phase 3 trial in children with Phelan-McDermid syndrome.

Neuren set for FDA talks on trial to treat developmental genetic disorders

Neuren Pharmaceuticals is set to enter talks with the Us Food and Drug Administration about its upcoming trial.

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Neuren has confirmed it's received "positive" FDA responses for its Phase III trial to treat children with Phelan-McDermid syndrome.

Buyers (Bids)

Sellers (Offers)

Top Stories

Featured News